Net loss of $3.86 million for the six months ended March 31, 2026, compared to a profit in the prior year.
G&A expenses as a percentage of revenue increased to 11.9% from 9.1% due to revenue volume decline.
Company is managing a $122M term loan with a maturity date of December 2027.
The latest 10-Q reveals a company at a critical inflection point, where the success of the investment thesis depends entirely on the speed of its transition. The immediate financial impact of losing legacy VA and HHS contracts has been severe, resulting in a net loss for the quarter and a significant drop in half-year revenue. However, the company has avoided a goodwill impairment charge thus far, and its Adjusted EBITDA remains positive, suggesting that the underlying business is not yet in a death spiral. Investors must weigh the risk of a liquidity crunch against the potential for a high-margin rebirth. The massive backlog provides a cushion, but the erosion of the funded portion of that backlog is a red flag. The ultimate outcome will be determined by whether DLH can successfully replace lost commodity revenue with high-tech prime contracts before its 2027 debt obligations become insurmountable.